LUND, Sweden & TOKYO-- -- Camurus AB and Solasia Pharma K.K. jointly announced today that they have entered into a license and distribution agreement for episilA oral liquid, a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of some cancer therapies, as well as other oral lesions. As part of the agreement Solasia receives exclusive commercialization rights to episilA in Japan and China, where it has ongoing operations and is building a specialty pharmaceutical infrastructure in the area of oncology and cancer supportive care.
http://ift.tt/1EVTbAQ
http://ift.tt/1EVTbAQ
No comments:
Post a Comment